Eric S Xu
Overview
Explore the profile of Eric S Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
242
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lock I, Leisenring N, Floyd W, Xu E, Luo L, Ma Y, et al.
PLoS One
. 2025 Mar;
20(3):e0318856.
PMID: 40043089
Background: The tumor suppressor p53 (Trp53), also known as p53, is the most commonly mutated gene in cancer. Canonical p53 DNA damage response pathways are well characterized and classically thought...
2.
Blocker S, Mowery Y, Everitt J, Cook J, Cofer G, Qi Y, et al.
Front Oncol
. 2024 Jun;
14:1287479.
PMID: 38884083
Purpose: To identify significant relationships between quantitative cytometric tissue features and quantitative MR (qMRI) intratumorally in preclinical undifferentiated pleomorphic sarcomas (UPS). Materials And Methods: In a prospective study of genetically...
3.
Odhiambo D, Pittman A, Rickard A, Castillo R, Bassil A, Chen J, et al.
Int J Radiat Oncol Biol Phys
. 2023 Dec;
118(5):1315-1327.
PMID: 38104870
Purpose: Despite aggressive multimodal treatment that typically includes definitive or adjuvant radiation therapy (RT), locoregional recurrence rates approach 50% for patients with locally advanced human papillomavirus (HPV)-negative head and neck...
4.
Lock I, Leisenring N, Floyd W, Xu E, Luo L, Ma Y, et al.
bioRxiv
. 2023 Aug;
PMID: 37577531
Background: Tp53 is the most commonly mutated gene in cancer. Canonical Tp53 DNA damage response pathways are well characterized and classically thought to underlie the tumor suppressive effect of Tp53....
5.
Patel R, Mowery Y, Qi Y, Bassil A, Holbrook M, Xu E, et al.
Mol Cancer Ther
. 2022 Sep;
22(1):112-122.
PMID: 36162051
This study aims to investigate whether adding neoadjuvant radiotherapy (RT), anti-programmed cell death protein-1 (PD-1) antibody (anti-PD-1), or RT + anti-PD-1 to surgical resection improves disease-free survival for mice with...
6.
Wisdom A, Mowery Y, Hong C, Himes J, Nabet B, Qin X, et al.
Nat Commun
. 2020 Dec;
11(1):6410.
PMID: 33335088
Immunotherapy fails to cure most cancer patients. Preclinical studies indicate that radiotherapy synergizes with immunotherapy, promoting radiation-induced antitumor immunity. Most preclinical immunotherapy studies utilize transplant tumor models, which overestimate patient...
7.
Huang J, Chen M, Xu E, Luo L, Ma Y, Huang W, et al.
Sci Rep
. 2019 Nov;
9(1):17220.
PMID: 31748650
Cooperating gene mutations are typically required to transform normal cells enabling growth in soft agar or in immunodeficient mice. For example, mutations in Kras and transformation-related protein 53 (Trp53) are...
8.
Wisdom A, Hong C, Lin A, Xiang Y, Cooper D, Zhang J, et al.
Proc Natl Acad Sci U S A
. 2019 Aug;
116(37):18584-18589.
PMID: 31462499
Nearly two-thirds of cancer patients are treated with radiation therapy (RT), often with the intent to achieve complete and permanent tumor regression (local control). RT is the primary treatment modality...
9.
Chen M, Xu E, Leisenring N, Cardona D, Luo L, Ma Y, et al.
Sarcoma
. 2019 Aug;
2019:1340261.
PMID: 31427882
Myxoid liposarcoma is a malignant soft tissue sarcoma characterized by a pathognomonic t(12;16)(q13;p11) translocation that produces a fusion oncoprotein, FUS-CHOP. This cancer is remarkably sensitive to radiotherapy and exhibits a...
10.
Lee C, Oh P, Xu E, Ma Y, Kim Y, Daniel A, et al.
Int J Radiat Oncol Biol Phys
. 2018 Jul;
102(5):1569-1576.
PMID: 30056081
Purpose: The delivery of radiation therapy to cure gastrointestinal (GI) cancers is often limited by normal tissue toxicity of the GI tract. Studies using genetically engineered mice have demonstrated an...